Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2015

View Archived Issues

ChemoCentryx, a company focusing on chemoattractant receptors, reviews company outlook

Novel synthetic medium-size compounds mimic functions of antibodies

New evidence provided on SEMA4D as a promising target for MS

3SBio acquires contract manufacturer Sirton Pharmaceuticals

PXT-864 pleodrug improves biological AD-related features

RestorGenex compound granted FDA orphan status for glioblastoma multiforme

Aclaris Therapeutics reports data from phase IIb trial of A-101

Actavis to acquire Auden Mckenzie

Hybrigenics extends partnership with Servier for ubiquitin-specific protease inhibitors

Pfizer aims to improve access to Prevenar 13 in poorest countries

Redx Pharma patents Hedgehog signaling pathway inhibitors

Takeda reports development of RORgamma-t antagonists

Anti-IL-32 MAbs described in ImmunoQure patent

Academic researchers prepare and test ALK inhibitors

Abide Therapeutics divulges MGL inhibitors

National University of Singapore presents peptide inhibitors of FXI

NRX-1074 improves depression scores in phase I study

CF-602 shows promise for sexual dysfunction in preclinical studies

Cutanea Life Sciences initiates phase II trial of CLS-003 for cutaneous warts

PlantForm initiates financing round to fund development of biosimilars

Boehringer Ingelheim studies effect of tiotropium and olodaterol Respimat on COPD exacerbations

Forest initiates pediatric phase I/II trial of ceftaroline fosamil

Radius Health initiates phase I trial of RAD-1901 in breast cancer

Amgen and Onyx file applications to expand approval of carfilzomib in the E.U. and U.S.

Janssen closes collaboration and license agreement with MacroGenics for MGD-011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...